Unsupervised principal components analysis (PCA) separated patients with VEXAS syndrome from the other groups on dimension 2, driven by inflammatory cytokines (IL-6, IL-18), IL-1 receptor antagonist (IL-1RA) and myelomonocytic markers (calprotectin and galectin-3) (Fig. 4A). Here, IL18 is linked to VEXAS syndrome.